Cernilton® (Cernilton)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsp

Pills

Composition:

1 tablet contains:

Active substances: Graminex® G60 (water-soluble fraction of microbiologically fermented extract of plant pollens) - 60.00 mg; Graminex® GFX (fat-soluble fraction microbiologically fermented pollen extract) - 3.00 mg.

Excipients: microcrystalline cellulose - 237,80 mg, colloidal silicon dioxide - 5.60 mg magnesium stearate -3,60 mg.

Description:

Round, biconvex tablets from pale yellow to light yellow with small patches of darker, engraved brand logo on one side, with a specific smell.

Pharmacotherapeutic group:A means of treating benign prostatic hyperplasia of plant origin
ATX: & nbsp
  • Other drugs for the treatment of benign prostatic hyperplasia
    • Pharmacodynamics:

    Cernilton anti-inflammatory and anti-edematous action, contributes to the regulation of metabolic processes.

    One of the pharmacological properties of the drug is a dose-dependent inhibition of COX and 5-lipoxygenase, which leads to inhibition of inflammatory mediator synthesis cycle arachidonic acid: the prostaglandins and leukotrienes, and, as a consequence, to a decrease in inflammation and swelling of the prostate tissue. The drug helps to eliminate the pain syndrome.

    Cernilton has a muscle relaxant effect, which leads to a relaxation of the smooth muscle elements of the posterior wall of the urethra and an improvement in urination. The drug reduces the volume of the prostate gland by inhibiting 5-αreductase, selectively blocks α1-adrenoreceptors of smooth-muscle elements of the urethra, has an antiandrogenic effect. Promotes the improvement of erectile function.

    Indications:

    As part of complex therapy: acute and chronic prostatitis, benign prostatic hyperplasia, benign prostatic hyperplasia in combination with prostatitis.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Dosing and Administration:

    The drug is administered orally 30 minutes before meals, with a small amount of water.

    Acute prostatitis: 4 tablets 3 times a day. The duration of treatment is determined by the attending physician and is usually 3 months.

    Chronic prostatitis: 1 tablet 3-4 times a day. Duration of the course treatment is determined individually by the attending physician and is usually from 3 to 6 months.

    Benign prostatic hyperplasia: 2 tablets 3 times a day.The duration of the course of treatment is determined individually by the attending physician and is usually from 6 to 12 weeks, but can be increased to 6 months.

    Side effects:

    With increased individual sensitivity to the components of the drug, allergic reactions are possible; in rare cases, the appearance of nausea.

    Overdose:

    To date, cases of overdose have not been observed.

    Interaction:

    There is no information on the interaction of Cernilton with other drugs.

    Special instructions:

    The use of the drug for chronic bacterial prostatitis is possible only in combination with antibacterial agents, as directed and under the supervision of a doctor.

    Form release / dosage:Pills.
    Packaging:

    For 100 or 200 tablets with a packet of hydrogen sorbent in a bottle of dark glass with a plastic lid and a safety ring under the lid or in a bottle of white opaque high-density polyethylene (HDPE), closed with a screw cap made of opaque polypropylene (PP) and safety valve under the cover. The bottle is additionally sealed in plastic film. On 1 bottle together with the instruction on application place in a pack from a cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N014227 / 01
    Date of registration:06.06.2008
    The owner of the registration certificate:Gramyneks LL.S.Gramyneks LL.S. USA
    Manufacturer: & nbsp
    Representation: & nbspGrameenx-Pharma Group of Companies LLC Grameenx-Pharma Group of Companies LLC Russia
    Information update date: & nbsp08.03.16
    Illustrated instructions
      Instructions
      Up